SAN DIEGO, Jan. 21, 2026 /PRNewswire/ --The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in Humana Inc shares. Investors who purchased shares of Humana Inc. (NYSE: HUM) prior to July 2022 and continue to hold any of thoseNYSE: HUM shares have also certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. In June 2024, a Humana investor filed a lawsuit over alleged violations of securities laws by ...

Core Viewpoint - Humana Inc. is facing significant challenges in its Medicare Advantage business, leading to a projected loss in Q4 2025 and a decline in earnings per share (EPS) for fiscal 2026 [2][5][6]. Company Overview - Humana Inc. is a major health insurance and managed care company based in Louisville, Kentucky, with a market capitalization of approximately $32.9 billion [1]. Earnings Expectations - The company is expected to report a loss of $4.01 per share for fiscal Q4 2025, a decline of 85.7% from $2.16 per share in the same quarter last year [2]. - For fiscal 2025, analysts anticipate a profit of $17.08 per share, reflecting a 5.4% increase from $16.21 per share in fiscal 2024, but a decline of 28.9% year-over-year to $12.14 in fiscal 2026 [3]. Performance Comparison - Humana's stock has underperformed compared to the S&P 500 Index, which returned 16.9%, and the State Street SPDR S&P Health Care Services ETF, which gained 15% over the past 52 weeks [4]. Challenges Faced - The company has encountered ongoing difficulties in its Medicare Advantage business, including a downgrade in quality ratings for several major plans and higher-than-expected medical costs, which have negatively impacted profit margins [5]. - In Q3 2025, revenues increased by 11.1% year-over-year to $32.7 billion, but profits weakened due to rising medical utilization, with the adjusted benefit ratio rising to 91.1% and non-GAAP EPS falling by 22.1% year-over-year to $3.24 [6]. Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for Humana, with a mean price target of $286.50, indicating an upside potential of 4.8% [7].

Core Insights - Humana Inc. has partnered with Atlas Oncology Partners to enhance cancer care for Medicare beneficiaries, starting January 1, 2026, in Tennessee and Mississippi [1][9] Group 1: Partnership and Care Model - The Atlas Oncology care model offers a comprehensive suite of services to support patients throughout their cancer treatment journey, including on-site and virtual clinical support [2][9] - The model features locally managed interdisciplinary teams that provide high-value, wrap-around services, including proactive care coordination and counseling to address barriers to care [2][4] Group 2: Benefits and Impact - The partnership aims to improve health outcomes for Humana's Medicare Advantage members with cancer, potentially retaining existing customers and attracting new ones [6] - Increased adoption of Humana's plans is expected to boost its Medicare Advantage membership base, which stood at 5.8 million as of September 30, 2025, and contribute to higher premium revenues, which advanced 9% year over year in the first nine months of 2025 [7] Group 3: Market Performance - Humana's shares have increased by 23.5% over the past six months, outperforming the industry growth of 12.7% [8]

Core Viewpoint - Humana Inc. is set to release its financial results for the fourth quarter of 2025 on February 11, 2026, along with management remarks in PDF format [1] Financial Results Announcement - The financial results will be available at 6:00 a.m. Eastern time on the specified date [1] - A live question-and-answer session will take place at 8:00 a.m. Eastern time to discuss the quarterly results and earnings guidance for 2026 [1] Access to Information - A webcast of the 4Q25 earnings call can be accessed through Humana's Investor Relations page [1]

Core Viewpoint - Health insurance companies experienced a slight increase in stock prices after market hours on January 9, with notable gains among major players in the sector [1] Group 1: Company Performance - UnitedHealth's stock price rose by 0.8% [1] - CVS Health Group's stock price increased by 0.4% [1] - Humana's stock price saw a rise of 0.9% [1] - Centene's stock price also increased by 0.9% [1]

Core Viewpoint - The article summarizes significant analyst rating changes that could impact market trends, highlighting upgrades, downgrades, and new coverage ratings for various companies [1][6]. Upgrades - Barclays upgraded Whirlpool (W) from "Neutral" to "Overweight," raising the target price from $104 to $123, citing accelerated market share growth expected in 2025 and continuation into 2026 [5]. - Oppenheimer upgraded McDonald's (MCD) from "Market Perform" to "Outperform," setting a target price of $355, with a more optimistic outlook for the restaurant sector in 2026 despite a poor performance in 2025 [5]. - Barclays upgraded Lowe's (LOW) from "Neutral" to "Overweight," increasing the target price from $259 to $285, based on an expected improvement in non-essential goods demand due to upcoming tax policy changes [5]. - Piper Sandler upgraded Hershey (HSY) from "Neutral" to "Overweight," raising the target price from $193 to $213, noting lower cocoa costs and the removal of cocoa tariffs, which provide flexibility for reinvestment and growth [5]. - Bank of America upgraded Regeneron Pharmaceuticals (REGN) from "Underperform" to "Buy," significantly raising the target price from $627 to $860, as previous concerns regarding Eylea SD have been addressed [5]. Downgrades - Jefferies downgraded First Solar (FSLR) from "Buy" to "Hold," lowering the target price from $269 to $260 due to limited visibility on orders and emerging strategic issues [10]. - Oppenheimer downgraded Yum Brands (YUM) from "Outperform" to "Market Perform," with no target price set, as the stock's risk-reward profile has become balanced after a 13% increase in 2025 [10]. - Montreal Bank Capital Markets downgraded Union Pacific Railroad (UNP) from "Outperform" to "Market Perform," reducing the target price from $270 to $255, citing high uncertainty regarding regulatory outcomes and weak freight demand [10]. - Piper Sandler downgraded Deckers Outdoor (DECK) from "Neutral" to "Underweight," lowering the target price from $100 to $85, as the company has increased discount promotions on its core brands [10]. - Wells Fargo downgraded Humana (HUM) from "Overweight" to "Neutral," setting a target price of $290, due to uncertainties regarding profit margin targets for 2026 [10]. New Coverage - Argus Research initiated coverage on grocery delivery platform Instacart (CART) with a "Buy" rating and a target price of $52, highlighting revenue growth and recent profitability achievements [11]. - Citigroup initiated coverage on Natera (NTRA) with a "Buy" rating and a target price of $300, citing significant growth potential [11]. - Link Consulting initiated coverage on Galecto (GLTO) with an "Outperform" rating and a target price of $46, noting its acquisition of Damola Therapeutics to advance its oncology pipeline [11]. - Wolfe Research initiated coverage on Apogee Therapeutics (APGE) with a "Market Perform" rating, without a target price, predicting mixed catalysts for the stock in 2026 [11]. - Mizuho Securities initiated coverage on Palvella Therapeutics (PVLA) with an "Outperform" rating and a target price of $205, based on positive clinical trial data for its drug Qtorin [11].

Core Viewpoint - Wells Fargo downgraded the rating of health insurance company Hamanah from "Outperform" to "Hold," while maintaining the target price at $290 [1] Group 1 - The downgrade reflects a shift in the investment outlook for Hamanah, indicating potential concerns about its future performance [1] - The target price of $290 suggests that Wells Fargo sees limited upside potential from the current trading levels [1]

Core Insights - Whales have adopted a bearish stance on Humana, with 34% of investors opening trades with bearish expectations compared to 23% with bullish expectations [1] - The price target for Humana has been identified in the range of $170.0 to $360.0 over the last three months based on options activity [2] - Recent options activity indicates significant interest in both puts and calls, with a total of 16 puts valued at $1,455,459 and 10 calls valued at $426,208 [1] Options Activity - The largest observed options trades for Humana include multiple put trades with varying sentiments, indicating both bullish and bearish expectations [6] - The volume and open interest trends for Humana's options provide insights into liquidity and investor interest at specific strike prices [3] Company Overview - Humana is one of the largest private health insurers in the US, focusing on government-sponsored programs such as Medicare and Medicaid, and also offers various healthcare services [7] - Analysts have set an average price target of $287.5 for Humana, with one analyst upgrading their rating to Buy and adjusting the target to $313 [9][11]

Core Viewpoint - Humana Inc. (HUM) is at a critical juncture as rising medical costs and Medicare Advantage (MA) challenges have impacted investor sentiment, raising the question of whether the worst is already priced in [1] Performance Summary - Over the past year, HUM shares have increased by 1.8%, outperforming the broader industry which saw a decline of 28.3%, and also faring better than peers like UnitedHealth Group (UNH) and Centene Corporation (CNC), which fell by 35% and 32.6% respectively [2][8] - Despite ongoing volatility, the relative strength of HUM suggests that investors are not ready to abandon the stock [2] Near-Term Pressures - Humana is experiencing pressure from elevated medical costs, particularly in its Medicare Advantage segment, with higher utilization trends and inpatient admissions affecting its medical care ratio [6][8] - Regulatory uncertainty regarding MA reimbursement rates continues to be a concern, limiting potential upside in the near term [6] Long-Term Tailwinds - Humana's long-term investment case is supported by its scale, the aging U.S. population, and initiatives focused on value-based care [9] - The company remains a leading Medicare Advantage provider with strong brand recognition and an integrated care delivery platform [9] Valuation Insights - Humana's current forward 12-month P/E ratio is 21.26X, which is above its five-year median of 17.69X and the industry average of 15.63X [10] - The stock is priced below the average analyst target of $284.87, indicating a potential upside of about 10% [11] Earnings Estimates - The Zacks Consensus Estimate for HUM's 2025 EPS is $17.08, reflecting a year-over-year growth of 5.4%, while revenues are expected to increase by 10% to $128.94 billion [12] Conclusion - Humana lacks a clear catalyst for immediate recovery, but the stock's recent sell-off may have already accounted for much of the operational and regulatory risks [13] - For current investors, maintaining positions may be the most rational strategy, while new investors are advised to monitor cost trends and reimbursement clarity before entering [14]

Company Overview - Khaveen Investments is a global Investment Advisory Firm focused on serving the investment needs of high-net-worth individuals, corporations, associations, and institutions [1] - The firm is a registered investment adviser with the Securities Exchange Commission (SEC) [1] - It offers a range of services including market and security research, business valuation, and wealth management [1] Investment Strategy - The flagship Macroquantamental Hedge Fund maintains a diversified portfolio with exposure to hundreds of investments across various asset classes, geographies, sectors, and industries [1] - The investment approach integrates top-down and bottom-up analysis, utilizing three core strategies: global macro, fundamental, and quantitative [1] Core Expertise - Khaveen Investments specializes in disruptive technologies that are transforming modern industries [1] - Key focus areas include Artificial Intelligence, Cloud Computing, 5G, Autonomous and Electric Vehicles, FinTech, Augmented and Virtual Reality, and the Internet of Things (IoT) [1]